Early Ventricular Arrhythmias After LVAD Implantation Is the Strongest Predictor of 30-Day Post-Operative Mortality.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
08 2019
Historique:
received: 11 01 2019
revised: 22 05 2019
accepted: 30 05 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 24 10 2020
Statut: ppublish

Résumé

This study aimed to evaluate incidence, clinical significance, and predictors of early ventricular arrhythmias (VAs) in left ventricular assist device (LVAD) recipients. LVAD implantation is increasingly used in patients with end-stage heart failure. Early VAs may occur during the 30-day post-operative period, but many questions remain unanswered regarding their incidence and clinical impact. This observational study was conducted in 19 centers between 2006 and 2016. Early VAs were defined as sustained ventricular tachycardia and/or ventricular fibrillation occurring <30 days post-LVAD implantation and requiring appropriate implantable cardioverter-defibrillator therapy, external electrical shock, or medical therapy. A total of 652 patients (median age: 59.8 years; left ventricular ejection fraction: 20.7 ± 7.4%; HeartMate 2: 72.8%; HeartWare: 19.5%; Jarvik 2000: 7.7%) were included in the analysis. Early VAs occurred in 162 patients (24.8%), most frequently during the first week after LVAD implantation. Multivariable analysis identified history of VAs prior to LVAD and any combined surgery with LVAD as 2 predictors of early VAs. The occurrence of early VAs with electrical storm was the strongest predictor of 30-day post-operative mortality, associated with a 7-fold increase of 30-day mortality. However, in patients discharged alive from hospital, occurrence of early VAs did not influence long-term survival. Early VAs are common after LVAD implantation and increase 30-day post-operative mortality, without affecting long-term survival. Further studies will be needed to analyze whether pre- or pre-operative ablation of VAs may improve post-operative outcomes. (Determination of Risk Factors of Ventricular Arrhythmias After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device [ASSIST-ICD]; NCT02873169).

Sections du résumé

OBJECTIVES
This study aimed to evaluate incidence, clinical significance, and predictors of early ventricular arrhythmias (VAs) in left ventricular assist device (LVAD) recipients.
BACKGROUND
LVAD implantation is increasingly used in patients with end-stage heart failure. Early VAs may occur during the 30-day post-operative period, but many questions remain unanswered regarding their incidence and clinical impact.
METHODS
This observational study was conducted in 19 centers between 2006 and 2016. Early VAs were defined as sustained ventricular tachycardia and/or ventricular fibrillation occurring <30 days post-LVAD implantation and requiring appropriate implantable cardioverter-defibrillator therapy, external electrical shock, or medical therapy.
RESULTS
A total of 652 patients (median age: 59.8 years; left ventricular ejection fraction: 20.7 ± 7.4%; HeartMate 2: 72.8%; HeartWare: 19.5%; Jarvik 2000: 7.7%) were included in the analysis. Early VAs occurred in 162 patients (24.8%), most frequently during the first week after LVAD implantation. Multivariable analysis identified history of VAs prior to LVAD and any combined surgery with LVAD as 2 predictors of early VAs. The occurrence of early VAs with electrical storm was the strongest predictor of 30-day post-operative mortality, associated with a 7-fold increase of 30-day mortality. However, in patients discharged alive from hospital, occurrence of early VAs did not influence long-term survival.
CONCLUSIONS
Early VAs are common after LVAD implantation and increase 30-day post-operative mortality, without affecting long-term survival. Further studies will be needed to analyze whether pre- or pre-operative ablation of VAs may improve post-operative outcomes. (Determination of Risk Factors of Ventricular Arrhythmias After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device [ASSIST-ICD]; NCT02873169).

Identifiants

pubmed: 31439296
pii: S2405-500X(19)30476-1
doi: 10.1016/j.jacep.2019.05.025
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02873169']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

944-954

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Vincent Galand (V)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Erwan Flécher (E)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Vincent Auffret (V)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Camille Pichard (C)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Stéphane Boulé (S)

Department of Cardiology and Cardiac Surgery, CHU Lille, Institut Coeur-Poumons, Lille, France.

André Vincentelli (A)

Department of Cardiology and Cardiac Surgery, CHU Lille, Institut Coeur-Poumons, Lille, France.

Anne Rollin (A)

Department of Cardiology, Department of Cardiac Surgery, CHU de Toulouse, Toulouse, France.

Pierre Mondoly (P)

Department of Cardiology, Department of Cardiac Surgery, CHU de Toulouse, Toulouse, France.

Laurent Barandon (L)

Hôpital Cardiologique du Haut-Lévêque, Université Bordeaux II, Bordeaux, France.

Mathieu Pernot (M)

Hôpital Cardiologique du Haut-Lévêque, Université Bordeaux II, Bordeaux, France.

Michel Kindo (M)

Department of Cardiovascular Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Thomas Cardi (T)

Department of Cardiovascular Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Philippe Gaudard (P)

Department of Anesthesiology and Critical Care Medicine, PhyMedExp, University of Montpellier, INSERM, CNRS, Department of Cardiac Surgery, University of Montpellier, CHU Montpellier, Montpellier, France.

Philippe Rouvière (P)

Department of Anesthesiology and Critical Care Medicine, PhyMedExp, University of Montpellier, INSERM, CNRS, Department of Cardiac Surgery, University of Montpellier, CHU Montpellier, Montpellier, France.

Thomas Sénage (T)

Department of Cardiology and Heart Transplantation Unit, CHU Nantes, France.

Nicolas Jacob (N)

Department of Cardiology and Heart Transplantation Unit, CHU Nantes, France.

Pascal Defaye (P)

Department of Cardiology and Cardiovascular Surgery, CHU Michallon, Grenoble, France.

Olivier Chavanon (O)

Department of Cardiology and Cardiovascular Surgery, CHU Michallon, Grenoble, France.

Constance Verdonk (C)

Department of Cardiology and Cardiac Surgery, Bichat-Hospital, Paris, France.

Walid Ghodbane (W)

Department of Cardiology and Cardiac Surgery, Bichat-Hospital, Paris, France.

Edeline Pelcé (E)

Department of Cardiac Surgery, La Timone Hospital, Marseille, France.

Vlad Gariboldi (V)

Department of Cardiac Surgery, La Timone Hospital, Marseille, France.

Matteo Pozzi (M)

Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.

Jean-François Obadia (JF)

Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.

Arnaud Savouré (A)

Department of Cardiology and Cardiovascular Surgery, Hospital Charles Nicolle, Rouen, France.

Frédéric Anselme (F)

Department of Cardiology and Cardiovascular Surgery, Hospital Charles Nicolle, Rouen, France.

Gerard Babatasi (G)

Department of Cardiology and Cardiac Surgery, University Hospital of Caen, University of Caen, Caen, France.

Annette Belin (A)

Department of Cardiology and Cardiac Surgery, University Hospital of Caen, University of Caen, Caen, France.

Fabien Garnier (F)

Department of Cardiology and Cardiac Surgery, University Hospital, Dijon, France.

Marie Bielefeld (M)

Department of Cardiology and Cardiac Surgery, University Hospital, Dijon, France.

David Hamon (D)

Department of Cardiology and Cardiac Surgery, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, Créteil, France.

Nicolas Lellouche (N)

Department of Cardiology and Cardiac Surgery, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, Créteil, France.

Bertrand Pierre (B)

Department of Cardiology and Cardiac Surgery, Tours University Hospital, Tours, France.

Thierry Bourguignon (T)

Department of Cardiology and Cardiac Surgery, Tours University Hospital, Tours, France.

Romain Eschalier (R)

Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Nicolas D'Ostrevy (N)

Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Marie-Cécile Bories (MC)

Cardiology Department, European Georges Pompidou Hospital, Paris, France.

Eloi Marijon (E)

Cardiology Department, European Georges Pompidou Hospital, Paris, France.

Fabrice Vanhuyse (F)

Department of Cardiology and Cardiac Surgery, CHU de Nancy, Hopital de Brabois, Nancy, France.

Hugues Blangy (H)

Department of Cardiology and Cardiac Surgery, CHU de Nancy, Hopital de Brabois, Nancy, France.

Jean-Philippe Verhoye (JP)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Christophe Leclercq (C)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France.

Raphaël P Martins (RP)

Univ Rennes, CHU Rennes, INSERM, LTSI - UMR 1099, Rennes, France. Electronic address: raphael.martins@chu-rennes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH